Cardiac mri detection of a rare case of familial cardiac amyloidosis (Ser23asn): Case report with literature review

Reports in Medical Imaging

Volumn 3, Issue , 2010, Pages 123-127

  Daoko, Joseph ^a   Elnahar, Yaser ^a   El Kersh, Karim ^a   Mohammad, Naser ^a   Shamoon, Fayez ^a  

^a ST MICHAEL S MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; Cardiac disease; Diagnosis; Genetics; Mutation

Indexed keywords

ASPARAGINE; GADOLINIUM PENTETATE MEGLUMINE; PREALBUMIN; SERINE;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CINE MAGNETIC RESONANCE IMAGING; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DISEASE DURATION; DYSPNEA; ELECTROCARDIOGRAM; EXERCISE TEST; FAMILIAL AMYLOIDOSIS; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; HEART AMYLOIDOSIS; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PERFUSION; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR HYPOKINESIA; MALE; MEDICAL HISTORY; PERICARDIAL EFFUSION; PERUVIAN; RECURRENT DISEASE; SUDDEN CARDIAC DEATH; THORAX PAIN; TTR GENE;

EID: 85012951090     PISSN: None     EISSN: 11791586     Source Type: Journal    
DOI: 10.2147/RMI.S14552     Document Type: Article

References (27)

1. Connors LH, Théberge R, Skare J, Costello CE, Falk RH, Skinner M. A new transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient. Amyloid. 1999;6(2):114-118.
2. Kyle RA. Amyloidosis: the last three centuries. In: Bely M, Apathy A, editors. Amyloid and Amyloidosis. New York, NY: Springer; 2001:10-13.
3. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature-2002. Amyloid. 2002;9(3):197-200.
4. Rivera RJ, Vicenty S. Cardiac manifestations of amyloid disease. Bol Asoc Med PR. 2008;100(4):60-70.
5. Sunde M, Blake CC. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys. 1998;31(1):1-39.
6. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid. 2007;14(3):179-183.
7. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73-85.
8. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(4):518-522.
9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596.
10. Hammarström P, Sekijima Y, White JT, et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry. 2003;42(22):6656-6663.
11. Sekijima Y, Hammarstrom P, Matsumura M, et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest. 2003;83(3): 409-417.
12. Mitsuhashi S, Yazaki M, Tokuda T, et al. Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis. Amyloid. 2005;12(4):216-225.
13. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003;17(6):909-927.
14. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1): 45-59.
15. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78(1): 74-82.
16. Hamilton JA, Benson MD. Transthyretin: a review from a structural prospective. Cell Mol Life Sci. 2001;58(10):1491-1521.
17. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000;109(3):181-188.
18. Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131(11): 838-841.
19. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80(9):1242-1245.
20. Morner S, Hellman U, Suhr OB, Kazzam E, Waldenström A. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med. 2005;258(3):225-230.
21. Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30(4):1046-1051.
22. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cadiol. 2004;43(3): 410-415.
23. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-2060.
24. Pennell DJ, Maceira AM. Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2(12):1378-1380.
25. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155-164.
26. Syed I, Glockner J, Araoz PA, et al. The presence and pattern of late gadolinium enhancement on cardiac MRI in amyloidosis is associated with other markers of prognosis. Circulation. 2008;118: S_1032.
27. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2(12):1369-1377.